With a measles outbreak in Kentucky spreading to Fayette County, health officials are stressing the importance of vaccination ...

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C. difficile bacteria and spores induces positive antigen titers in humans that recognize the bacteriaInitial ...

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is ...

Felzartamab was previously investigated in two Phase 2 studies, M-PLACE, reductions in aPLA2R titers were observed in most patients as early as one week (median reduction of 45%), with responses (>50% ...

Lenzing's TENCEL™ branded lyocell fibers with Micro technology continues to set the benchmark in the textile industry with ...

About the Phase 1 study The Phase 1 clinical pharmacology study is a double-blind, randomized, placebo-controlled, two-part trial to assess the safety, tolerability, and immunogenicity of up to 3 ...

Since the emergence of the Zika virus epidemic in 2014 and the associated novel sequalae that emerged, much has been learned about the effects of antenatal exposure to Zika virus. Zika virus in ...

The use of TNF-α inhibitors among patients with hidradenitis suppurativa did not affect seroconversion following mRNA vaccination for COVID-19.

By focusing on twins and patients with lupus and Parkinson’s disease, a Mexican consortium is generating critical data to ...